Xvivo Perfusion AB (publ) (XVIVO.ST)
SEK 465.0
(1.97%)
SEK 465.0
(1.97%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 141.6 Million SEK | 32.88% |
| 2022 | 106.56 Million SEK | 37.35% |
| 2021 | 77.59 Million SEK | 30.73% |
| 2020 | 59.35 Million SEK | 35.29% |
| 2019 | 43.87 Million SEK | 20.57% |
| 2018 | 36.38 Million SEK | 18.51% |
| 2017 | 30.7 Million SEK | -11.14% |
| 2016 | 34.55 Million SEK | 20.82% |
| 2015 | 28.59 Million SEK | 9.19% |
| 2014 | 26.19 Million SEK | 45.58% |
| 2013 | 17.99 Million SEK | 34.51% |
| 2012 | 13.37 Million SEK | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q2 | 173.43 Million SEK | 14.88% |
| 2024 Q3 | 190.12 Million SEK | 9.62% |
| 2024 Q1 | 150.96 Million SEK | 6.61% |
| 2023 FY | 141.6 Million SEK | 32.88% |
| 2023 Q3 | 145.61 Million SEK | 17.76% |
| 2023 Q2 | 123.65 Million SEK | 11.86% |
| 2023 Q4 | 141.6 Million SEK | -2.76% |
| 2023 Q1 | 110.54 Million SEK | 3.74% |
| 2022 Q4 | 106.56 Million SEK | 18.41% |
| 2022 Q1 | 70.29 Million SEK | -9.4% |
| 2022 FY | 106.56 Million SEK | 37.35% |
| 2022 Q3 | 89.99 Million SEK | 20.47% |
| 2022 Q2 | 74.7 Million SEK | 6.27% |
| 2021 FY | 77.59 Million SEK | 30.73% |
| 2021 Q1 | 65.22 Million SEK | 9.89% |
| 2021 Q2 | 72.73 Million SEK | 11.52% |
| 2021 Q3 | 78.99 Million SEK | 8.61% |
| 2021 Q4 | 77.59 Million SEK | -1.78% |
| 2020 Q2 | 48.02 Million SEK | -6.78% |
| 2020 Q3 | 53.44 Million SEK | 11.29% |
| 2020 Q4 | 59.35 Million SEK | 11.05% |
| 2020 Q1 | 51.51 Million SEK | 17.43% |
| 2020 FY | 59.35 Million SEK | 35.29% |
| 2019 Q4 | 43.87 Million SEK | -6.88% |
| 2019 FY | 43.87 Million SEK | 20.57% |
| 2019 Q1 | 48.21 Million SEK | 32.5% |
| 2019 Q2 | 46.63 Million SEK | -3.27% |
| 2019 Q3 | 47.11 Million SEK | 1.02% |
| 2018 Q3 | 36.14 Million SEK | 24.79% |
| 2018 FY | 36.38 Million SEK | 18.51% |
| 2018 Q1 | 27.72 Million SEK | -9.71% |
| 2018 Q2 | 28.96 Million SEK | 4.48% |
| 2018 Q4 | 36.38 Million SEK | 0.67% |
| 2017 FY | 30.7 Million SEK | -11.14% |
| 2017 Q1 | 35.44 Million SEK | 2.58% |
| 2017 Q2 | 33.07 Million SEK | -6.67% |
| 2017 Q3 | 32.16 Million SEK | -2.75% |
| 2017 Q4 | 30.7 Million SEK | -4.56% |
| 2016 Q1 | 25 Million SEK | -12.56% |
| 2016 Q4 | 34.55 Million SEK | 7.82% |
| 2016 Q2 | 27.09 Million SEK | 8.34% |
| 2016 Q3 | 32.04 Million SEK | 18.29% |
| 2016 FY | 34.55 Million SEK | 20.82% |
| 2015 Q1 | 26.93 Million SEK | 2.86% |
| 2015 Q2 | 29.13 Million SEK | 8.15% |
| 2015 Q4 | 28.59 Million SEK | -9.37% |
| 2015 FY | 28.59 Million SEK | 9.19% |
| 2015 Q3 | 31.55 Million SEK | 8.31% |
| 2014 Q1 | 16.4 Million SEK | -8.8% |
| 2014 Q2 | 19.3 Million SEK | 17.63% |
| 2014 Q3 | 21.34 Million SEK | 10.58% |
| 2014 Q4 | 26.19 Million SEK | 22.72% |
| 2014 FY | 26.19 Million SEK | 45.58% |
| 2013 Q4 | 17.99 Million SEK | -1.03% |
| 2013 Q2 | 13.63 Million SEK | 16.95% |
| 2013 FY | 17.99 Million SEK | 34.51% |
| 2013 Q1 | 11.65 Million SEK | -12.85% |
| 2013 Q3 | 18.17 Million SEK | 33.35% |
| 2012 Q4 | 13.37 Million SEK | 0.0% |
| 2012 FY | 13.37 Million SEK | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| Acarix AB (publ) | 6.83 Million SEK | -1970.537% |
| ADDvise Group AB (publ) | 121.2 Million SEK | -16.835% |
| ADDvise Group AB (publ) | 121.2 Million SEK | -16.835% |
| Arcoma AB | 28.02 Million SEK | -405.241% |
| Bactiguard Holding AB (publ) | 29.64 Million SEK | -377.65% |
| BICO Group AB (publ) | 493.1 Million SEK | 71.283% |
| Boule Diagnostics AB (publ) | 62.4 Million SEK | -126.929% |
| CellaVision AB (publ) | 126.03 Million SEK | -12.35% |
| Clinical Laserthermia Systems AB (publ) | 6.11 Million SEK | -2215.683% |
| Chordate Medical Holding AB (publ) | 1.77 Million SEK | -7896.065% |
| C-Rad AB (publ) | 64.09 Million SEK | -120.911% |
| Duearity AB (publ) | 4.15 Million SEK | -3304.761% |
| Dignitana AB (publ) | 7.41 Million SEK | -1810.212% |
| Episurf Medical AB (publ) | 3.7 Million SEK | -3727.135% |
| Getinge AB (publ) | 6.41 Billion SEK | 97.793% |
| Scandinavian Real Heart AB (Publ) | -1.68 Million SEK | 8511.931% |
| Iconovo AB (publ) | -4.86 Million SEK | 3012.464% |
| Integrum AB (publ) | 22.36 Million SEK | -533.237% |
| Luxbright AB (publ) | 8000.00 SEK | -1769950.0% |
| Mentice AB (publ) | 14.1 Million SEK | -903.999% |
| OssDsign AB (publ) | 4.3 Million SEK | -3190.056% |
| Paxman AB (publ) | 19.99 Million SEK | -608.055% |
| Promimic AB (publ) | 330 Thousand SEK | -42810.303% |
| Qlife Holding AB (publ) | 7.29 Million SEK | -1841.909% |
| SciBase Holding AB (publ) | 11.91 Million SEK | -1088.053% |
| ScandiDos AB (publ) | 22.69 Million SEK | -524.081% |
| Sectra AB (publ) | 36.59 Million SEK | -287.002% |
| Sedana Medical AB (publ) | 42.97 Million SEK | -229.503% |
| Senzime AB (publ) | 20.34 Million SEK | -596.185% |
| SpectraCure AB (publ) | 1.00 SEK | -14160399900.0% |
| Stille AB | 66.55 Million SEK | -112.769% |
| Vitrolife AB (publ) | 413 Million SEK | 65.713% |